IP Library › Assignment 070403/0862
Patent Assignment
Reel/Frame 070403/0862

Security Interest

Recorded: 2025-03-04 Pages: 76
Assignor
AFFINI-T THERAPEUTICS, INC.
Executed: 2025-03-03
Assignee
CATALIO NEXUS FUND III, LP
512 W. 22ND STREET, 5TH FLOOR, NEW YORK, NEW YORK, 10011
Covered Properties (94)
Chimeric Receptors Comprising IL7R Domains
Application: 63/377,230 →
Host Cells Bearing Kras Binding Protein and Knockout of Endogenous Tcr and Methods of Use Thereof
Application: 63/483,231 →
Host Cells Bearing Kras Binding Protein and Knockout of Endogenous Tcr and Methods of Use Thereof
Application: 63/492,146 →
Host Cells Bearing Kras Binding Protein and Knockout of Endogenous Tcr and Methods of Use Thereof
Application: 63/496,356 →
Host Cells Bearing Kras Binding Protein and Knockout of Endogenous Tcr and Methods of Use Thereof
Application: 63/503,403 →
Host Cells Bearing Kras Binding Protein and Knockout of Endogenous Tcr and Methods of Use Thereof
Application: 63/545,883 →
Compositions and Methods for Treating Neoplasia
Application: 63/563,841 →
Compositions and Methods for Treating Neoplasia
Application: 63/692,987 →
Compositions and Methods for Treating Neoplasia
Application: 63/604,709 →
Compositions and Methods for Treating Neoplasia
Application: 63/575,241 →
Compositions and Methods for Treating Neoplasia
Application: 63/716,389 →
Title Not Available
Application: 63/716,394 →
Title Not Available
Application: 63/728,062 →
Binding Proteins and Engineered Cells Specific for Ras Neoantigens and Uses Thereof
Application: 63/344,965 →
Binding Proteins and Engineered Cells Specific for Ras Neoantigens and Uses Thereof
Application: 63/380,527 →
Binding Proteins and Engineered Cells Specific for Ras Neoantigens and Uses Thereof
Application: 63/501,973 →
Binding Proteins and Engineered Cells Specific for Neoantigens and Uses Thereof
Application: 18/955,703 →
Publication: US 2025/0152717
Binding Proteins Specific for Kras Neoantigens and Uses Thereof
Application: 62/808,248 →
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 17/408,340 →
Publication: US 2021/0379150
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 17/643,410 →
Publication: US 2022/0160832
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 17/832,214 →
Publication: US 2023/0139737
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 18/662,926 →
Publication: US 2025/0114433
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 63/342,025 →
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 63/380,551 →
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 63/488,758 →
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 18/945,416 →
Publication: US 2025/0177531
Immunomodulatory Fusion Proteins and Uses Thereof
Application: 62/473,282 →
Immunomodulatory Fusion Proteins and Uses Thereof
Application: 62/629,663 →
Immunomodulatory Fusion Proteins and Uses Thereof
Application: 16/494,729 →
Publication: US 2020/0009190
Immunomodulatory Fusion Proteins and Uses Thereof
Application: 18/339,197 →
Publication: US 2024/0218379
Binding Proteins Specific for Mutant P53 and Uses Thereof
Application: 63/482,282 →
T Cell Receptors Targeting Ras Mutations and Uses Thereof
Application: 63/192,783 →
T Cell Receptors Targeting Ras Mutations and Uses Thereof
Application: 18/517,835 →
Publication: US 2024/0091361
T Cell Receptors Targeting TP53 Hotspot Mutations and Uses Thereof
Application: 63/515,497 →
Enzymes with Ruvc Domains
Application: 16/917,837 →
Publication: US 2020/0332273
Enzymes with Ruvc Domains
Application: 16/917,838 →
Publication: US 2020/0332274
Enzymes with Ruvc Domains
Application: 17/193,173 →
Publication: US 2022/0033791
Enzymes with Ruvc Domains
Application: 17/402,426 →
Publication: US 2022/0220460
Enzymes with Ruvc Domains
Application: 18/335,481 →
Publication: US 2024/0117330
Enzymes with Ruvc Domains
Application: 18/668,543 →
Publication: US 2024/0344045
Multiplex Editing with Cas Enzymes
Application: 18/459,729 →
Publication: US 2025/0075233
Multiplex Editing with Cas Enzymes
Application: 63/163,510 →
Multiplex Editing with Cas Enzymes
Application: 63/186,506 →
Multiplex Editing with Cas Enzymes
Application: 63/241,916 →
Enzymes with Ruvc Domains
Application: 18/586,929 →
Publication: US 2024/0200047
Class Ii, Type V Crispr Systems
Application: 17/706,466 →
Publication: US 2022/0290187
Class Ii, Type V Crispr Systems
Application: 17/929,978 →
Publication: US 2023/0227857
Class Ii, Type V Crispr Systems
Application: 18/302,387 →
Publication: US 2024/0093239
Class Ii, Type V Crispr Systems
Application: 18/816,810 →
Publication: US 2025/0059568
Anti-CD3-Binding Domains and Antibodies Comprising Them, and Methods for Their Generation and Use
Application: 62/503,315 →
Anti-CD3-Binding Domains and Antibodies Comprising Them, and Methods for Their Generation and Use
Application: 16/611,832 →
Publication: US 2020/0190189
Anti-CD3-Binding Domains and Antibodies Comprising Them, and Methods for Their Generation and Use
Application: 18/054,588 →
Publication: US 2023/0151097
High Affinity Anti-CD3 Antibodies, and Methods for Their Generation and Use
Application: 62/858,949 →
High Affinity Anti-CD3 Antibodies, and Methods for Their Generation and Use
Application: 17/617,046 →
Publication: US 2023/0002487
Engineered Ph-Dependent Anti-CD3 Antibodies, and Methods for Their Generation and Use
Application: 62/858,968 →
Engineered Ph-Dependent Anti-CD3 Antibodies, and Methods for Their Generation and Use
Application: 17/617,019 →
Publication: US 2022/0380463
Anti-CD3 Antibodies
Application: 63/245,499 →
Anti-CD3 Antibodies
Application: 18/692,097 →
Publication: US 2024/0317858
Retroviral Transduction Using Poloxamers
Patent: 9,771,599 →
Application: 14/381,586 →
Publication: US 2015/0064788
Retroviral Transduction Using Poloxamers
Application: 15/713,422 →
Publication: US 2018/0016600
Retroviral Transduction Using Poloxamers
Application: 16/941,780 →
Publication: US 2021/0010026
Retroviral Transduction Using Poloxamers
Application: 18/085,751 →
Publication: US 2023/0130635
Retroviral Transduction Using Poloxamers
Application: 18/887,203 →
Publication: US 2025/0011814
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 17/408,340 →
Publication: US 2021/0379150
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Application: 17/643,410 →
Publication: US 2022/0160832
Immunomodulatory Fusion Proteins and Uses Thereof
Application: 16/494,729 →
Publication: US 2020/0009190
Enzymes with Ruvc Domains
Application: 16/917,838 →
Publication: US 2020/0332274
Enzymes with Ruvc Domains
Application: 16/917,837 →
Publication: US 2020/0332273
Enzymes with Ruvc Domains
Application: 17/193,173 →
Publication: US 2022/0033791
Class Ii, Type V Crispr Systems
Application: 17/706,466 →
Publication: US 2022/0290187
Class Ii, Type V Crispr Systems
Application: 18/302,387 →
Publication: US 2024/0093239
Anti-CD3-Binding Domains and Antibodies Comprising Them, and Methods for Their Generation and Use
Application: 16/611,832 →
Publication: US 2020/0190189
Retroviral Transduction Using Poloxamers
Patent: 9,771,599 →
Application: 14/381,586 →
Publication: US 2015/0064788
Retroviral Transduction Using Poloxamers
Application: 15/713,422 →
Publication: US 2018/0016600
Retroviral Transduction Using Poloxamers
Application: 16/941,780 →
Publication: US 2021/0010026
Chimeric Receptors Comprising Interleukin 7 Receptor (IL7R) Domains
Host Cells Bearing Kras Binding Protein and Knockout of Endogenous Tcr and Methods of Use Thereof
Compositions and Methods for Treating Neoplasia
Binding Proteins and Engineered Cells Specific for Neoantigens and Uses Thereof
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Binding Proteins Specific for Ras Neoantigens and Uses Thereof
Immunomodulatory Fusion Proteins and Uses Thereof
Binding Proteins Specific for Mutant P53 and Uses Thereof
T Cell Receptors Targeting Ras Mutations and Uses Thereof
T Cell Receptors Targeting TP53 Hotspot Mutations and Uses Thereof
Enzymes with Ruvc Domains
Enzymes with Ruvc Domains
Enzymes with Ruvc Domains
Class Ii, Type V Crispr Systems
Anti-CD3-Binding Domains and Antibodies Comprising Them, and Methods for Their Generation and Use
High Affinity Anti-CD3 Antibodies, and Methods for Their Generation and Use
Engineered Ph-Dependent Anti-CD3 Antibodies, and Methods for Their Generation and Use
Anti-CD3 Antibodies
Multiplex Editing with Cas Enzymes
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 25, 2017
From: ODA, SHANNON K.; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 042511/0989 →
Assignment of Assignor's Interest Mar 15, 2018
From: ODA, SHANNON K.; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 045241/0862 →
Assignment of Assignor's Interest Oct 2, 2019
From: PERRET, RACHEL; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 050607/0001 →
Assignment of Assignor's Interest Nov 25, 2019
From: ODA, SHANNON K.; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 051109/0320 →
Assignment of Assignor's Interest Feb 19, 2020
From: CHAPUIS, AUDE; STROMNES, INGUNN
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 051864/0611 →
Assignment of Assignor's Interest Aug 6, 2020
From: THOMAS, BRIAN; BROWN, CHRISTOPHER; KANTOR, ROSE; DEVOTO, AUDRA
To: METAGENOMI IP TECHNOLOGIES, LLC
Reel/Frame 053425/0298 →
Assignment of Assignor's Interest Jun 28, 2021
From: KLEBANOFF, CHRISTOPHER A.; CHANDRAN, SMITA S.
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 056692/0298 →
Corrective Assignment to Correct the Assignee's Name and Address Previously Recorded at Reel: 053425 Frame: 0298. Assignor(S) Hereby Confirms the Assignment. Apr 26, 2022
From: THOMAS, BRIAN; BROWN, CHRISTOPHER; KANTOR, ROSE; DEVOTO, AUDRA
To: METAGENOMI, INC.
Reel/Frame 060377/0687 →
Assignment of Assignor's Interest May 23, 2022
From: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH; MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 059991/0381 →
Assignment of Assignor's Interest May 23, 2022
From: KLEBANOFF, CHRISTOPHER A.
To: MEMORIAL SLOAN-KETTERING CANCER CENTER; SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH; MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
Reel/Frame 059991/0249 →
Merger and Change of Name Jun 3, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060271/0765 →
Assignment of Assignor's Interest Jun 3, 2022
From: PERRET, RACHEL; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.; CHAPUIS, AUDE G.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 060100/0724 →
Assignment of Assignor's Interest Jun 29, 2022
From: PERRET, RACHEL; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.; CHAPUIS, AUDE G.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 060358/0738 →
Merger and Change of Name Jul 11, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060478/0647 →
Assignment of Assignor's Interest Aug 3, 2022
From: SHAPIRO, GARY; HE, XINGYUE; DRAIN, ALLISON; QU, HONGJING
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 060703/0785 →
Merger and Change of Name Aug 17, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 061204/0523 →
Merger and Change of Name Aug 22, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 061299/0469 →
Assignment of Assignor's Interest Sep 12, 2022
From: METAGENOMI, INC.
To: METAGENOMI IP TECHNOLOGIES, LLC
Reel/Frame 061410/0063 →
Assignment of Assignor's Interest Oct 5, 2022
From: SHAPIRO, GARY; HE, XINGYUE
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 061319/0623 →
Merger Oct 11, 2022
From: METAGENOMI IP TECHNOLOGIES, LLC
To: METAGENOMI, INC.
Reel/Frame 061383/0584 →
Assignment of Assignor's Interest Oct 20, 2022
From: SCHMITT, THOMAS; GREENBERG, PHILIP; MARTINOV, TIJANA
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 061486/0393 →
Assignment of Assignor's Interest Oct 31, 2022
From: SHAPIRO, GARY; HE, XINGYUE; DRAIN, ALLISON; QU, HONGJING
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 061600/0564 →
Assignment of Assignor's Interest Apr 11, 2023
From: HOFFMANN, MICHELE; LIANG, JINSHENG
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 063293/0004 →
Assignment of Assignor's Interest Apr 11, 2023
From: HOFFMANN, MICHELE; LIANG, JINSHENG
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 063292/0858 →
Assignment of Assignor's Interest May 12, 2023
From: SCHMITT, THOMAS M.; GREENBERG, PHILIP D.; MARTINOV, TIJANA; PERRET, RACHEL
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 063630/0204 →